Argos Therapeutics Reports Fourth Quarter and Year-End 2014 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St climbs after Fed's Waller says he could support rate hold
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
Argos Therapeutics (ARGS) Receives Funding from NIH DAIDS for AGS-004 Phase 2a
April 1, 2015 8:38 AM EDTArgos Therapeutics (NASDAQ: ARGS) announced that the NIH Division of AIDS (DAIDS) has approved $6.6 million in funding for an investigator-initiated Phase 2a adult eradication study of AGS-004, the company's investigational fully personalized immunotherapy for HIV.
Eliminating the latent virus reservoir has been shown to be an essential goal in efforts to eradicate HIV. Research has shown that histone deacetylase (HDAC) inhibitors can... More
Argos Therapeutics (ARGS) Misses Q3 EPS by 10c
March 30, 2015 4:11 PM EDTArgos Therapeutics (NASDAQ: ARGS) reported Q3 EPS of ($0.83), $0.10 worse than the analyst estimate of ($0.73). Revenue for the quarter came in at $303 thousand versus the consensus estimate of $670 thousand.
For earnings history and earnings-related data on Argos Therapeutics (ARGS) click here.
... More